From Minerals to Medicine

Salient is a Texas-based company formed in 2007 to explore the pharmaceutical application of its proprietary composition of a rare, all-natural mineral. This composition has been proven to adsorb a range of toxins and inflammatory proteins commonly associated with diarrhea and other GI issues.

Salient’s compound, CASAD™, is envisioned to be a “platform” product effective across a spectrum of conditions. From cancer therapy-induced diarrhea and oral mucositis to infectious disease and chronic GI conditions, it also has the potential to be used as a rescue agent for other drugs with toxic side effects.

Our Mission

Severe diarrhea and other GI-related issues can be debilitating for people on drug therapies, those dealing with a variety of infectious diseases or those living with inflammatory GI diseases. In some situations, side effects, such as chronic diarrhea, can become life threatening. At Salient, our mission is to improve patient health, the probability of primary therapy success and recovery rates by preventing and/or treating the side effects often associated with diseases and therapy regimens. 

The Need for Salient’s CASAD™

Severe diarrhea and other GI-related issues can be debilitating for people on drug therapies, those dealing with a variety of infectious diseases or those living with inflammatory GI diseases. In some situations, side effects, such as chronic diarrhea, can become life threatening. At Salient, our mission is to improve patient health, the probability of primary therapy success and recovery rates by preventing and/or treating the side effects often associated with diseases and therapy regimens.

Product Development

With support from the National Cancer Institute (NCI), Salient is actively conducting a Phase II clinical trial to test the safety and efficacy of CASAD™. This trial is currently underway at M.D. Anderson Hospital and other sites with preliminary results expected in mid-2012. In this first trial, Salient is testing the efficacy of its product to prevent and/or treat diarrhea associated with Irinotecan®, a common part of the treatment regimen for colorectal cancer.

Salient is also in the preliminary stages of testing CASAD™ in treating diarrhea associated with Clostridium difficile and inflammatory bowel disease. Preclinical studies for oral mucositis and radiation proctitis have also been conducted.

Click here to get the latest clinical trial news.

Funding

Salient is a privately held C-corporation funded by a major academic institution, the Texas Emerging Technology Fund and a group of private investors.

Click here for additional investor information.

Houston Technology Center Client

Salient is a former client company of the Houston Technology Center (HTC), a business accelerator and the largest technology business incubator in Texas. HTC accelerates the commercialization of emerging technology companies in the Greater Houston area. A 501(C)(3)non-profit organization, HTC assists Houston-based entrepreneurs within several key sectors: Energy, Information Technology, Life Sciences, Nanotechnology and NASA/Aerospace technologies, by providing in-depth business guidance, access to capital and service providers, and entrepreneurial education.

For more information, visit www.houstontech.org.